lymphodepleting chemotherapy (LD)
Showing 1 - 25 of >10,000
Advanced Renal Cell Carcinoma, Advanced Mesothelioma, Advanced Osteosarcoma Trial in Houston (CAR.70/IL15-transduced CB-derived
Not yet recruiting
- Advanced Renal Cell Carcinoma
- +2 more
- CAR.70/IL15-transduced CB-derived NK cells
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jan 27, 2023
Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma Trial in Houston, Milwaukee (CAR-GPC3 T
Recruiting
- Hepatocellular Carcinoma
- +3 more
- CAR-GPC3 T Cells
-
Dallas, Texas
- +2 more
Dec 20, 2022
Non-hodgkin Lymphoma,B Cell, Multiple Myeloma, Acute Lymphoblastic Leukemia, Adult Trial in Atlanta (Fludarabine,
Not yet recruiting
- Non-hodgkin Lymphoma,B Cell
- +2 more
-
Atlanta, GeorgiaCaitlin Guzowski
Jun 9, 2023
Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma Trial in Tampa (TBio-4101, Cyclophosphamide, Fludarabine)
Recruiting
- Metastatic Melanoma
- +9 more
- TBio-4101
- +3 more
-
Tampa, FloridaMoffitt Cancer Center
Jan 24, 2023
Hematological Malignancy Trial in Houston (Fludarabine Phosphate, Cyclophosphamide, CAR.5/IL15-transduced CB-NK cells)
Not yet recruiting
- Hematological Malignancy
- Fludarabine Phosphate
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
Advanced Solid Tumor Trial in Shanghai (B4T2-001 autologous CAR-T)
Recruiting
- Advanced Solid Tumor
- B4T2-001 autologous CAR-T
-
Shanghai, China/Shanghai, China
- +1 more
Oct 3, 2023
B-Cell Lymphoma, MDS (MDS), Acute Myeloid Leukemia (AML) Trial in Houston (Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells,
Not yet recruiting
- B-Cell Lymphoma
- +2 more
- Cyclophosphamide
- +2 more
-
Houston, TexasM D Anderson Cancer Center
May 12, 2022
Synovial Sarcoma Trial in Houston (Fludarabine phosphate, NY-ESO-1 TCR/IL-15 NK, Cyclophosphamide)
Not yet recruiting
- Synovial Sarcoma
- Fludarabine phosphate
- +2 more
-
Houston, TexasMD Anderson Cancer Center
Oct 9, 2023
Follicular Lymphoma (FL) Trial (biological, drug, other)
Not yet recruiting
- Follicular Lymphoma (FL)
- Tisagenlecleucel
- +4 more
- (no location specified)
May 24, 2023
R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,
Recruiting
- R/R CD19-Positive B-Cell Malignancies
- +2 more
- CNTY-101
- +2 more
-
Detroit, Michigan
- +1 more
Dec 21, 2022
DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma Trial in Minneapolis (E7777)
Recruiting
- DLBCL
- +3 more
-
Minneapolis, MinnesotaUniversity of Minnesota, Masonic Cancer Center
Jul 1, 2022
B-Lymphoid Malignancies, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia Trial in Houston (Fludarabine,
Active, not recruiting
- B-Lymphoid Malignancies
- +3 more
- Fludarabine
- +4 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
Aug 1, 2022
Solid Tumor Trial in Washington (Tumor-associated antigen-specific T cell (TAA-T))
Recruiting
- Solid Tumor
- Tumor-associated antigen-specific T cell (TAA-T)
-
Washington, District of ColumbiaChildren's National Hospital
Oct 24, 2022
Glioblastoma Trial (5x10(7) CART-EGFR-IL13Ra2, 1x107 CART-EGFR-IL13Ra2, 1x10(8) CART-EGFR-IL13Ra2)
Not yet recruiting
- Glioblastoma
- 5x10(7) CART-EGFR-IL13Ra2
- +5 more
- (no location specified)
Jan 7, 2022
Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus
Not yet recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CD19 specific Chimeric Antigen Receptor T Cell
-
Columbus, OhioNationwide Children's Hospital
Mar 9, 2023
Lymphocytes, Tumor-Infiltrating Trial in Saint Petersburg (Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide,
Not yet recruiting
- Lymphocytes
- Tumor-Infiltrating
- Tumor Infiltrating Lymphocytes, Fludarabine, Cyclophosphamide, Interleukin-2
-
Saint Petersburg, Florida
- +1 more
Sep 15, 2023
Peripheral T Cell Lymphoma (PTCL), Cell Therapy Trial in United States (MT-101, MT-101 + Conditioning (Lymphodepleting)
Recruiting
- Lymphoma, T-Cell, Peripheral
- +4 more
- MT-101
- MT-101 + Conditioning (Lymphodepleting) Chemotherapy
-
Duarte, California
- +8 more
Jan 27, 2023
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston
Not yet recruiting
- Refractory Aggressive B-cell Lymphomas
- +12 more
- ACALABRUTINIB
- +2 more
-
Boston, Massachusetts
- +1 more
Oct 13, 2022
Multiple Myeloma, Smoldering Multiple Myeloma Trial in Boston (Ciltacabtagene Autoleucel, Cyclophosphamide, Fludarabine
Not yet recruiting
- Multiple Myeloma
- Smoldering Multiple Myeloma
- Ciltacabtagene Autoleucel
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Mar 2, 2023
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma Trial in Philadelphia (MOv19-BBz CAR T cells, Alpha Folate
Recruiting
- Ovarian Cancer
- +2 more
- MOv19-BBz CAR T cells
- Alpha Folate Receptor expression test
-
Philadelphia, PennsylvaniaUniversity of Pennsylvania Health System
Sep 12, 2022
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Duarte (CS1-CAR T Therapy, Cyclophosphamide, Fludarabine)
Recruiting
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- CS1-CAR T Therapy
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 15, 2021
Neuroblastoma Trial (GD2 CAR T cells)
Not yet recruiting
- Neuroblastoma
- GD2 CAR T cells
- (no location specified)
Aug 5, 2023
Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)
Not yet recruiting
- Acute Lymphoid Leukemia
- +4 more
- fludarabine
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 17, 2022
Multiple Myeloma Trial in Worldwide (bb2121)
Active, not recruiting
- Multiple Myeloma
- bb2121
-
San Francisco, California
- +47 more
Jul 18, 2022